Atara Biotherapeutics Inc. (ATRA)
ATRA trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1604464/000119312526108361/0001193125-26-108361-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ATRA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2014 |
| SEC CIK | 0001604464 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $120.8M |
| Net income | $32.7M |
| Operating income | $35.9M |
| Net margin | 27.1% |
| Operating margin | 29.7% |
| Revenue growth | -6.3% |
| Cash | $8.5M |
| Total assets | $20.2M |
| P/E (computed) | 2.0× |
| P/S (computed) | 0.5× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Accordingly, we have concluded that substantial doubt exists with respect to our ability to continue as a going concern for at least 12 months after the issuance of the accompanying condensed consolidated financial statements." | 10-Q 2026-11-10 |
| Cash and burn | $4.1M cash; operating cash flow -$3.2M a quarter. | Report 2026-09-30 |
| Shares outstanding | 10,188,438 (2026-11-06); 7,210,235 a year earlier; 101,922,250 three years earlier. 3y figure adjusted for split (1-for-25 overall). | Cover page 2026-11-06 |
| Reverse splits, 3 years | 1; latest 1-for-25 on 2024-06-20 | Source 2024-06-20 |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 2 424B5 takedowns, 1 at the market | Latest 2026-05-12 |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-05-01 |
| Auditor | Deloitte & Touche LLP, San Francisco, California, United States | PCAOB Form AP 2026-03-25 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $5.7M, sold $3.9M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $1.2M | -$2.2M | -$879K | $4.1M | No debt tags | $4.0M | 10-Q 2026-11-10 |
| Q2 2026 2026-06-30 | $630K | -$4.8M | -$3.3M | $3.2M | No debt tags | $6.2M | 10-Q 2026-08-12 |
| Q1 2026 2026-03-31 | $516K | -$4.1M | -$3.1M | $8.4M | No debt tags | $23.1M | 10-Q 2026-05-12 |
| Q4 2025 2025-12-31 | $1.6M | -$3.4M | -$5.7M | $8.5M | No debt tags | $120.8M | 10-K 2026-03-16 |
| Q3 2025 2025-09-30 | $3.5M | -$4.3M | -$9.8M | $5.7M | No debt tags | $151.9M | 10-Q 2025-11-12 |
| Q2 2025 2025-06-30 | $17.6M | $2.4M | -$7.3M | $16.9M | No debt tags | $188.7M | 10-Q 2026-08-12 |
| Q1 2025 2025-03-31 | $98.1M | $38.0M | -$28.1M | $13.8M | No debt tags | $199.7M | 10-Q 2026-05-12 |
| Q4 2024 2024-12-31 | $32.8M | -$12.7M | -$24.5M | $25.0M | No debt tags | $128.9M | 10-K 2026-03-16 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-11-10 |
| Latest annual report | 10-K | 2026-03-16 |
| Latest quarterly / interim | 10-Q | 2026-11-10 |
| Latest current report | 8-K | 2026-11-10 |
| Latest proxy | DEF 14A | 2026-04-24 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -2.2% |
| 1 month | -17.2% |
| 3 months | -9.5% |
| Year to date | -57.4% |
| 1 year | -42.5% |
| From 52-week high | -57.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CSBR | Champions Oncology Inc. | $4.68 | -0.53% | $65.1M |
| CRDF | Cardiff Oncology Inc. | $0.8477 | +16.75% | $65.9M |
| OKYO | OKYO Pharma Limited | $1.18 | -12.96% | $61.7M |
| NMRA | Neumora Therapeutics Inc. | $0.3695 | -13.85% | $69.4M |
| CGTX | Cognition Therapeutics Inc. | $0.6388 | -6.03% | $60.8M |
| PMCB | PharmaCyte Biotech Inc. | $5.57 | -16.62% | $59.8M |
| AVXL | Anavex Life Sciences Corp. | $0.8176 | -12.42% | $75.8M |
| TNYA | Tenaya Therapeutics Inc. | $0.3336 | -4.47% | $76.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier